Aimei Health Technology Co., Ltd. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The filing describes Aimei as a Cayman Islands blank-check company (SPAC), not an operating healthcare business. It had not commenced operations and had no operating revenue. Its stated focus is to seek a business combination, with an intended emphasis on healthcare innovation.
Financial results and position
- Income: Net income was $755,500, comprising $909,132 of interest income from Trust Account investments, less $153,632 of formation and operating costs. Basic and diluted income per share was $0.08.
- Revenue and margins: No operating revenue was reported; operating margins are not meaningful for this pre-combination SPAC.
- Cash flow: Net cash used in operating activities was $166,970. Cash outside the Trust Account declined from $580,717 at December 31, 2023 to $413,747 at March 31, 2024.
- Liquidity and assets: At quarter-end, the Company reported $413,747 in operating cash, $70,798,980 in the Trust Account, and working capital of approximately $402,244. Total assets were $71,279,696.
- Liabilities and debt: Total liabilities were $768,472, including $78,472 of current accrued expenses and $690,000 of deferred underwriting compensation payable upon a completed business combination. The Company reported no long-term debt and no outstanding working-capital loans.
- Equity: Stockholders’ deficit was $287,756. The balance sheet separately reports $70,798,980 of redeemable shares as temporary equity.
Changes and comparability
The Trust Account balance increased from $69,889,848 at December 31, 2023 to $70,798,980 at March 31, 2024, primarily reflecting investment income. Cash outside the Trust Account fell by $166,970, while accrued expenses increased from $24,841 to $78,472. The filing does not provide a comparable Q1 2023 income statement or cash-flow period; therefore, year-over-year operating comparisons are unavailable.
Outlook, risks, and notable disclosures
- Management said no specific business combination was under consideration and that the Company had not had substantive discussions with a prospective target. It expects to use cash outside the Trust Account for operating costs and target-search and transaction expenses.
- The Company generally has 12 months from its December 6, 2023 IPO closing to complete a business combination, with provisions for up to twelve one-month extensions. If it fails to complete a transaction within the permitted period, it must cease operations, redeem public shares, and liquidate.
- Management believes available working capital and borrowing capacity should cover anticipated needs before a business combination, but additional financing may be needed and is not assured. The Sponsor and its affiliates may provide working-capital loans but are not obligated to do so.
- Management concluded that failure to complete a business combination in the prescribed period raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements contain no adjustments for the outcome of this uncertainty.
- The Sponsor has agreed to indemnify the Trust Account for certain claims that reduce it below $10.10 per public share, subject to exceptions. The Company has not verified the Sponsor’s ability to meet the obligation and believes the Sponsor may be unlikely to satisfy it.
- Disclosure controls and procedures were deemed not effective as of March 31, 2024. No material change in internal control over financial reporting during the quarter was reported.
- No legal proceedings or subsequent events requiring adjustment or disclosure were reported. No formal financial guidance was provided.
Investor facts to verify
- Confirm the business-combination deadline, extension conditions, and current progress toward identifying a target.
- Track cash available outside the Trust Account and whether additional financing or Sponsor loans become necessary.
- Review public-share redemption levels and the Trust Account balance in future filings, including the impact of any claims or withdrawals.
- Assess remediation of the disclosed ineffective disclosure controls and any subsequent updates to the going-concern assessment.
- Note that 9,026,000 ordinary shares were reported issued and outstanding as of May 13, 2024; rights may convert into additional shares upon a completed business combination.